Lyn­dra Ther­a­peu­tics eyes $180M Se­ries D for po­ten­tial 2026 launch of once-week­ly schiz­o­phre­nia med

With a Phase III tri­al now un­der­way for a once-week­ly, long-act­ing ver­sion of the an­tipsy­chot­ic med risperi­done, Lyn­dra Ther­a­peu­tics is eye­ing a large Se­ries D to push it through a 2025 NDA fil­ing with the goal of tak­ing it to mar­ket in 2026.

The biotech has closed the first tranche of the round, slight­ly over $20 mil­lion with the help of in­sid­ers, and is an­gling for $180 mil­lion to­tal, Jes­si­ca Ballinger, pres­i­dent and op­er­at­ing chief, told End­points News on the side­lines of this year’s BIO con­fab in Boston. Lyn­dra is cap­i­tal­iz­ing on slow-re­lease tech­nol­o­gy out of the MIT lab of Bob Langer, who is known in many cir­cles but more broad­ly for work on the de­liv­ery tech for the mR­NA Covid-19 vac­cines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER